Incidental deep soft tissue leiomyoma of the groin - a case report and comprehensive review of literature.

Leiomyomas are rare, benign tumors arising from smooth muscle cells. Due to the heterogeneous anatomical locations, as well as clinical and radiological findings, early and correct diagnosis is usually tricky. The clinical symptoms depend on the anatomical structure the tumors are compromising by their growth.

Pretherapeutic Comparative Dosimetry of Lu-rhPSMA-7.3 and Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.

Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands allow for labeling with F and radiometals for endoradiotherapy. rhPSMA-7.3 has been designated as a lead compound with promising preclinical data for Lu-rhPSMA-7.

Modeling and Predicting Tumor Response in Radioligand Therapy.

The aim of this work was to develop a theranostic method that allows prediction of prostate-specific membrane antigen (PSMA)-positive tumor volume after radioligand therapy (RLT) based on a pretherapeutic PET/CT measurement and physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling at the example of RLT using Lu-labeled PSMA for imaging and therapy (PSMA I&T). A recently developed PBPK model for Lu-PSMA I&T RLT was extended to account for tumor (exponential) growth and reduction due to irradiation (linear quadratic model). Data from 13 patients with metastatic castration-resistant prostate cancer were retrospectively analyzed.

[Assessment of Occupational Problems in Neurological Rehabilitation].

The so-called Würzburg Screening (WS) is recommended for assessing occupational problems among rehabilitation patients. However, it is unclear whether it can be used in neurological rehabilitation. Data of the WS as well as of a medical opinion of occupational problems (both assessed at the beginning of rehabilitation) was compared with prognoses of occupation at the end of rehabilitation.

Radiation Dosimetry for Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is increasingly used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed doses for normal organs and tumor lesions using Lu-PSMA I&T (I&T is imaging and therapy) in patients undergoing up to 4 cycles of radioligand therapy. Results were compared with pretherapeutic Glu-NH-CO-NH-Lys-(Ahx)-[Ga(HBEDCC)] (Ga-PSMA-HBED-CC) PET.